Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) – Pipeline Review, H2 2017’, provides in depth analysis on Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Oncology, Cardiovascular and Hematological Disorders under development targeting Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2)

The report reviews Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

MolMed SpA

Nippon Kayaku Co Ltd

Pharmaleads SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) - Overview 6

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) - Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 12

Products under Development by Universities/Institutes 15

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) - Therapeutics Assessment 17

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) - Companies Involved in Therapeutics Development 22

MolMed SpA 22

Nippon Kayaku Co Ltd 22

Pharmaleads SA 23

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) - Drug Profiles 24

NGR-hTNF - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

PL-265 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

PL-37 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Recombinant Protein to Inhibit CD13 for Lymphoma and Solid Tumor - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Small Molecules to Inhibit ANPEP for Oncology - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

STR-324 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

ubenimex - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) - Dormant Products 40

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) - Discontinued Products 42

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) - Product Development Milestones 43

Featured News & Press Releases 43

Jun 29, 2017: Pharmaleads Reports Positive Phase I SAD Data with its Dual ENKephalinase Inhibitor PL265 for the Treatment of Neuropathic Pain 43

May 17, 2017: Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema 43

May 15, 2017: Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension 44

May 12, 2017: Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor, at the ARVO 2017 Annual Meeting 45

May 05, 2017: Pharmaleads to Present PL265 for Ocular Pain Results at the ARVO 2017 Annual Meeting in Baltimore 46

May 04, 2017: Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City 46

Jan 03, 2017: Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension 47

Dec 23, 2016: The European Medicines Agency has Validated the Submission of Conditional Marketing Authorisation for NGR-hTNF 48

Dec 06, 2016: MolMed files a Conditional Marketing Authorisation in the European Union for NGR-hTNF 48

Jul 25, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema 49

Jul 18, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension 49

Mar 28, 2016: Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency 50

Dec 15, 2015: Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension 51

Nov 30, 2015: Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary 51

Sep 28, 2015: Pharmaleads Announces the Opening of French Sites in Its International Phase IIa Clinical Study of PL37 52

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indications, H2 2017 9

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Number of Products under Investigation by Universities/Institutes, H2 2017 15

Products under Investigation by Universities/Institutes, H2 2017 16

Number of Products by Stage and Mechanism of Actions, H2 2017 17

Number of Products by Stage and Route of Administration, H2 2017 19

Number of Products by Stage and Molecule Type, H2 2017 21

Pipeline by MolMed SpA, H2 2017 22

Pipeline by Nippon Kayaku Co Ltd, H2 2017 23

Pipeline by Pharmaleads SA, H2 2017 23

Dormant Products, H2 2017 40

Dormant Products, H2 2017 (Contd..1), H2 2017 41

Discontinued Products, H2 2017 42

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Stage and Mechanism of Actions, H2 2017 17

Number of Products by Routes of Administration, H2 2017 18

Number of Products by Stage and Routes of Administration, H2 2017 18

Number of Products by Molecule Types, H2 2017 20

Number of Products by Stage and Molecule Types, H2 2017 20

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports